SCHEMBL653891

SCHEMBL653891

Cc1cc(OC2CCC(C(=O)O)CC2)ccc1/N=C1/NC(=O)/C(=C/c2cnc(NC(=O)C3CC3)s2)S1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.41
LMNA P02545 2/20 0.41
NPSR1 Q6W5P4 5/20 0.41
RECQL P46063 1/20 0.41
TDP1 Q9NUW8 3/20 0.38
L3MBTL1 Q9Y468 3/20 0.38
MAPK1 P28482 1/20 0.38
ABL1 P00519 3/20 0.37
POLB P06746 3/20 0.37
HPGD P15428 2/20 0.37
RNASEL Q05823 1/20 0.35
PLA2G1B P04054 1/20 0.35
APEX1 P27695 1/20 0.35
ATG4B Q9Y4P1 1/20 0.35
PTP4A3 O75365 1/20 0.35
GPR119 Q8TDV5 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
KMT2A Q03164 2/20 0.34
PSMD14 O00487 1/20 0.34
MEN1 O00255 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL653892 1.00 MAPT (0.41) MAPTLMNANPSR1RECQLTDP1
SCHEMBL10176524 0.92 MAPT (0.40) MAPTLMNANPSR1RECQLTDP1
SCHEMBL10176480 0.92 MAPT (0.41) MAPTLMNANPSR1RECQLTDP1
SCHEMBL10176507 0.90 MAPT (0.40) MAPTLMNANPSR1RECQLTDP1
SCHEMBL698911 0.90 MAPT (0.38) MAPTLMNANPSR1RECQLTDP1
SCHEMBL10176547 0.89 MAPT (0.47) MAPTLMNANPSR1RECQLTDP1
SCHEMBL10176525 0.89 ABL1 (0.36) MAPTLMNANPSR1RECQLABL1
SCHEMBL650221 0.89 ABL1 (0.36) MAPTLMNANPSR1RECQLABL1
SCHEMBL10176532 0.88 PTPN7 (0.44) MAPTLMNANPSR1RECQLTDP1
SCHEMBL10176528 0.86 MAPT (0.42) MAPTLMNANPSR1RECQLTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2423204-A1 THIAZOLIDINONE DERIVATIVE SBI Biotech Co., Ltd. (JP) 2012-02-29 EP disclosed
US-8119812-B2 Thiazolidinone derivative SBI BIOTECH CO., LTD. (JP) 2012-02-21 US disclosed
US-8119812-B2 Thiazolidinone derivative SBI BIOTECH CO., LTD. (JP) 2012-02-21 US disclosed
US-8119812-B2 Thiazolidinone derivative SBI BIOTECH CO., LTD. (JP) 2012-02-21 US disclosed
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE SBI BIOTECH CO., LTD. (JP) 2011-08-04 US disclosed
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE SBI BIOTECH CO., LTD. (JP) 2011-08-04 US disclosed
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE SBI BIOTECH CO., LTD. (JP) 2011-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE CDC7, CDK17, CDCA2 MAPT 3657/4885LMNA 3772/4885NPSR1 4464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.